RPS20 and NRAS

Number of citations of the paper that reports this interaction (PubMedID 18624398)
14

Data Source:
BioGRID (two hybrid)

		RPS20	NRAS
Description		ribosomal protein S20	NRAS proto-oncogene, GTPase
Image
GO Annotations	Cellular Component	Nucleoplasm Cytosol Small Ribosomal Subunit Membrane Cytosolic Small Ribosomal Subunit Synapse Extracellular Exosome	Golgi Membrane Golgi Apparatus Plasma Membrane Membrane Extracellular Exosome Tertiary Granule Membrane
	Molecular Function	RNA Binding Structural Constituent Of Ribosome Protein Binding	GTPase Activity Protein Binding GTP Binding GDP Binding Protein-containing Complex Binding
	Biological Process	Nuclear-transcribed MRNA Catabolic Process, Nonsense-mediated Decay Translation Translational Initiation SRP-dependent Cotranslational Protein Targeting To Membrane Viral Transcription	MAPK Cascade Positive Regulation Of Endothelial Cell Proliferation Stimulatory C-type Lectin Receptor Signaling Pathway Ras Protein Signal Transduction Neutrophil Degranulation
Pathways		L13a-mediated translational silencing of Ceruloplasmin expression Peptide chain elongation SRP-dependent cotranslational protein targeting to membrane SRP-dependent cotranslational protein targeting to membrane Viral mRNA Translation Selenocysteine synthesis Major pathway of rRNA processing in the nucleolus and cytosol Translation initiation complex formation Formation of a pool of free 40S subunits Formation of the ternary complex, and subsequently, the 43S complex Ribosomal scanning and start codon recognition GTP hydrolysis and joining of the 60S ribosomal subunit Eukaryotic Translation Termination Regulation of expression of SLITs and ROBOs Response of EIF2AK4 (GCN2) to amino acid deficiency Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants
Drugs
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Multiple myeloma Adrenal carcinoma Thyroid cancer Hepatocellular carcinoma Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS Malignant melanoma
GWAS		Height ( 18391951) Systemic lupus erythematosus ( 28714469)	Autism ( 24189344)
Interacting Genes		18 interacting genes: APP BARD1 ECT2 HMGB1 IL7R MPHOSPH6 MPP6 NDRG1 NRAS PAXIP1 PIK3CA PLEKHO1 PTEN RABAC1 REEP6 SP3 SUN2 TRAF6	25 interacting genes: ACVR1 ARHGAP4 BCL2 DNAJB1 EEF1A1 HRAS LZTR1 MAPKAP1 MTOR PIK3CA PIK3CG PLCE1 RACGAP1 RAF1 RAP1GDS1 RASGRP2 RASSF5 RGL2 RPS20 SHOC2 SMAD4 SMURF2 SRI UBE2L3 WDR76
Entrez ID		6224	4893
HPRD ID		04728	01273
Ensembl ID		ENSG00000008988	ENSG00000213281
Uniprot IDs		P60866	P01111 Q5U091
PDB IDs		4UG0 4V6X 5A2Q 5AJ0 5FLX 5LKS 5OA3 5T2C 5VYC 6EK0 6FEC 6G51 6G53 6G5H 6G5I 6IP5 6IP6 6IP8 6OLE 6OLF 6OLG 6OLI 6OLZ 6OM0 6OM7 6QZP	2N9C 3CON 5UHV 6E6H
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?